New Two-Pronged attack aims to stop liver Cancer's return
NCT ID NCT06644937
Summary
This study is testing a combination treatment to prevent liver cancer from coming back after surgery in patients at high risk of recurrence. It combines a targeted liver procedure (TACE) with an oral medication (icaritin). The main goal is to see if this approach helps patients stay cancer-free for at least one year after their operation.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Zhujiang Hospital, Southern Medical University
RECRUITINGGuangzhou, Guangdong, 510000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.